PMID

Data

Article Title

Organization

The discovery of potent selective NPY Y(2) antagonists.

Janssen Research and Development

Discovery of microsomal triglyceride transfer protein (MTP) inhibitors with potential for decreased active metabolite load compared to dirlotapide.

Pfizer

Identification and structure-activity relationships of ortho-biphenyl carboxamides as potent Smoothened antagonists inhibiting the Hedgehog signaling pathway.

Novartis Institutes For Biomedical Research

In vitro and in vivo profile of 5-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-1H-indole-2-carboxylic acid benzylmethyl carbamoylamide (dirlotapide), a novel potent MTP inhibitor for obesity.

Pfizer

Discovery of potent and orally active MTP inhibitors as potential anti-obesity agents.

Pfizer

5-Carboxamido-1,3,2-dioxaphosphorinanes, potent inhibitors of MTP.

Bristol-Myers Squibb Pharmaceutical Research Institute

Diaminoindanes as microsomal triglyceride transfer protein inhibitors.

Novartis Institute For Biomedical Reasearch

A novel series of highly potent benzimidazole-based microsomal triglyceride transfer protein inhibitors.

The Bristol-Myers Squibb Pharmaceutical Research Institute